Recurrent bleeding during standard anticoagulant therapy in comorbid patients with atrial fibrillation: a clinical case report
Open Access
- 27 July 2023
- journal article
- research article
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 19 (3) , 248-253
Abstract
The question of the safety of direct oral anticoagulants (DOACs), despite their high efficacy in the prevention of thrombotic events in atrial fibrillation (AF), remains relevant due to the risk of developing hemorrhagic events while taking standard doses, which requires a thorough personalized approach. The article presents a clinical case of the development of spontaneous hematomas on the skin of the upper and lower extremities and hemarthrosis of the knee joint while taking 20 mg of rivaroxaban in a 72-year-old patient with AF without impaired renal and hepatic function. Due to the increase in the residual plasma concentration of rivaroxaban, a pharmacogenetic study and the Thrombodynamics (TD) test were performed. A pharmacogenetic study did not reveal significant gene polymorphisms associated with the metabolism of rivaroxaban. However, TD allowed us to confirm the presence of significant hypocoagulation at the peak of the residual blood concentration of the drug in the blood, which could cause recurrent hemorrhagic events in the patient. In addition, the patient is taking amiodarone at a dosage of 200 mg per day, which does not allow us to rule out drug-drug interaction, despite the inconsistency of the literature data.Keywords
This publication has 16 references indexed in Scilit:
- Efficacy and Safety Outcomes of Direct Oral Anticoagulants and Amiodarone in Patients with Atrial FibrillationThe American Journal of Medicine, 2018
- Rivaroxaban With and Without Amiodarone in Renal ImpairmentJACC, 2018
- Association Between Use of Non–Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial FibrillationJAMA, 2017
- Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: Results observed in four anticoagulation clinicsThrombosis Research, 2016
- Trends in Prescribing Oral Anticoagulants in Canada, 2008–2014Clinical Therapeutics, 2015
- Clinical Use of Rivaroxaban: Pharmacokinetic and Pharmacodynamic Rationale for Dosing Regimens in Different IndicationsDrugs, 2014
- Co‐administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjectsBritish Journal of Clinical Pharmacology, 2013
- Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitorBritish Journal of Clinical Pharmacology, 2010
- Body Weight Has Limited Influence on the Safety, Tolerability, Pharmacokinetics, or Pharmacodynamics of Rivaroxaban (BAY 59‐7939) in Healthy SubjectsThe Journal of Clinical Pharmacology, 2007
- National Surveillance of Emergency Department Visits for Outpatient Adverse Drug EventsJAMA, 2006